Preventing norovirus and Clostridium difficile gastroenteritis by engineered probiotic yeast Saccharomyces boulardii secreting multi-specific single-domain antibodies
通过分泌多特异性单域抗体的工程益生菌布拉酵母菌预防诺如病毒和艰难梭菌胃肠炎
基本信息
- 批准号:10320907
- 负责人:
- 金额:$ 60.86万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-01-22 至 2024-12-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAnimal Disease ModelsAnimal ModelAntibiotic ResistanceAntibiotic TherapyAntibioticsAntibodiesBindingBody Weight decreasedCarbohydratesCharacteristicsChromosomal InsertionClinicClinicalClostridium difficileCommunicable DiseasesDNA cassetteDataDevelopmentDiarrheaDiseaseDoseDried YeastDrug or chemical Tissue DistributionEncapsulatedEngineered ProbioticsEngineeringEnteralErythrocytesExcipientsFamily suidaeFormulationFutureGastroenteritisGenesGenomeGnotobioticGoalsHandHealth care facilityHemagglutinationHumanIn VitroIndividualInfectionInfection preventionInflammationIntestinal SecretionsIntestinesLeadLong-Term CareMediatingMethodsMonitorMorbidity - disease rateMusNorovirusOralOral AdministrationPatientsPrevention strategyPreventiveProbioticsProcessProductionProphylactic treatmentSaccharomycesSiteSymptomsTechnologyTestingTherapeuticToxinTraveler&aposs diarrheaVaccinesVariantViralViral Load resultVirulence FactorsVirus-like particleYeastsagedantibiotic-associated diarrheaantitoxinbasecapsulecommercializationenteric pathogengut microbiotahigh risk populationin vivomicrobiotamicrobiota transplantationmortalitynanobodiesnovelpassive antibodiespathogenpathogenic bacteriapreventscale uptooltransmission processvaccine accessvaccine development
项目摘要
Abstract
Human norovirus (hNoV) and Clostridium difficile (CD) represent two leading causes of acute gastroenteritis
worldwide with significant morbidity and mortality. The two infections (one viral and one bacterial) share many of
the same characteristics of transmission; and concurrent infections are particularly prevalent in the US in high-
risk populations, such as aged patients undergoing antibiotic treatments, hospitalized patients, or patients
staying in long-term care facilities. Despite great efforts in the development of vaccines against both infections,
to date there is still no single vaccine available on the market. We have developed a novel platform technology
against enteric bacterial pathogens by engineering a probiotic yeast, Saccharomyces boulardii, to secrete multi-
specific single-domain (VHH) antibodies, directly targeting bacterial virulence factors at the intestinal site of
infection. We have successfully applied this technology to target Clostridium difficile. The overall objective of this
project is to generate Sb strains secreting mSdAbs against both CD toxins and hNoV, generate proof-of-principle
efficacy data in relevant animal disease models, and develop clinic-compatible formulations for drying and
encapsulating the Sb-mSdAb strains. We hypothesize that oral administration of Sb-mSdAb strains secreting
mSdAb against hNoV and CD toxins will prevent their individual or concurrent infections. To test this hypothesis,
we propose to accomplish the following 3 specific aims: 1) Engineer Sb-mSdAb strains (Sb-aNoVCd) secreting
VHH fusions against both CD toxins and hNoVs. 2) Determine preventive efficacy of Sb-aNoVCd strains against
infections with hNoV and CD in gnotobiotic pigs. 3) Develop a formulation supporting yeast spray drying and
encapsulation. With the completion of proposed translational activities, we will have generated lead Sb-aNoVCd
strains and evaluated in vivo characteristics in mice and in gnotobiotic pigs which is the most appropriate animal
model of hNoV infection and disease. Should the key proof-of-principle efficacy data generated, future scale-up
efforts will be justified to include additional VHHs for generating broadly efficacious lead immunoprophylactic
strains and eventual commercialization of the yeast products against CD and hNoV gastroenteritis for which we
currently have no prophylaxis or vaccines.
抽象的
人类诺如病毒 (hNoV) 和艰难梭菌 (CD) 是急性胃肠炎的两个主要原因
在世界范围内具有显着的发病率和死亡率。这两种感染(一种病毒感染和一种细菌感染)有许多共同点
相同的传输特性;在美国,并发感染尤其普遍
危险人群,例如接受抗生素治疗的老年患者、住院患者或患者
住在长期护理机构中。尽管在开发针对这两种感染的疫苗方面付出了巨大努力,
迄今为止,市场上仍没有单一疫苗可用。我们开发了一种新颖的平台技术
通过改造益生菌酵母,布拉氏酵母菌,分泌多种细菌来对抗肠道细菌病原体
特异性单域(VHH)抗体,直接针对肠道部位的细菌毒力因子
感染。我们已成功地将这项技术应用于针对艰难梭菌。本次活动的总体目标
项目是生成针对 CD 毒素和 hNoV 分泌 mSdAb 的 Sb 菌株,并进行原理验证
相关动物疾病模型中的功效数据,并开发临床相容的干燥和干燥制剂
封装 Sb-mSdAb 菌株。我们假设口服 Sb-mSdAb 菌株分泌
针对 hNoV 和 CD 毒素的 mSdAb 将预防其单独或并发感染。为了检验这个假设,
我们建议实现以下 3 个具体目标:1)工程 Sb-mSdAb 菌株(Sb-aNoVCd)分泌
针对 CD 毒素和 hNoV 的 VHH 融合。 2) 确定 Sb-aNoVCd 菌株的预防功效
限生猪中的 hNoV 和 CD 感染。 3) 开发支持酵母喷雾干燥的配方
封装。随着拟议的转化活动的完成,我们将产生先导 Sb-aNoVCd
菌株并评估了小鼠和最合适动物的无菌猪的体内特性
hNoV感染和疾病模型。如果生成了关键的原理验证功效数据,未来的扩大规模
包括额外的 VHH 来产生广泛有效的先导免疫预防药物的努力将是合理的
菌株和针对 CD 和 hNoV 胃肠炎的酵母产品的最终商业化
目前没有预防措施或疫苗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hanping Feng其他文献
Hanping Feng的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Hanping Feng', 18)}}的其他基金
Characterization of neutralizing antitoxins and epitopes in Clostridium difficile patients
艰难梭菌患者中和抗毒素和表位的特征
- 批准号:
10549285 - 财政年份:2020
- 资助金额:
$ 60.86万 - 项目类别:
Preventing norovirus and Clostridium difficile gastroenteritis by engineered probiotic yeast Saccharomyces boulardii secreting multi-specific single-domain antibodies
通过分泌多特异性单域抗体的工程益生菌布拉酵母菌预防诺如病毒和艰难梭菌胃肠炎
- 批准号:
10540345 - 财政年份:2020
- 资助金额:
$ 60.86万 - 项目类别:
Characterization of neutralizing antitoxins and epitopes in Clostridium difficile patients
艰难梭菌患者中和抗毒素和表位的特征
- 批准号:
10319522 - 财政年份:2020
- 资助金额:
$ 60.86万 - 项目类别:
Probiotic yeast secreting single-domain antibodies to prevent Clostridium difficile and Campylobacter jejuni disease
益生菌酵母分泌单域抗体来预防艰难梭菌和空肠弯曲菌疾病
- 批准号:
10364713 - 财政年份:2019
- 资助金额:
$ 60.86万 - 项目类别:
Probiotic yeast secreting single-domain antibodies to prevent Clostridium difficile and Campylobacter jejuni disease
益生菌酵母分泌单域抗体来预防艰难梭菌和空肠弯曲菌疾病
- 批准号:
10584482 - 财政年份:2019
- 资助金额:
$ 60.86万 - 项目类别:
A Novel Humanized Tetra-specific Antibody against Clostridium difficile Infection
一种抗艰难梭菌感染的新型人源化四特异性抗体
- 批准号:
10432036 - 财政年份:2017
- 资助金额:
$ 60.86万 - 项目类别:
A Novel Humanized Tetra-specific Antibody against Clostridium difficile Infection
一种抗艰难梭菌感染的新型人源化四特异性抗体
- 批准号:
9362547 - 财政年份:2017
- 资助金额:
$ 60.86万 - 项目类别:
Toxemia and systemic disease in Clostridium difficile infection
艰难梭菌感染的毒血症和全身性疾病
- 批准号:
8664002 - 财政年份:2013
- 资助金额:
$ 60.86万 - 项目类别:
Epithelium, dendritic cells, and Clostridium difficile associated colitis
上皮、树突状细胞和艰难梭菌相关结肠炎
- 批准号:
7887611 - 财政年份:2010
- 资助金额:
$ 60.86万 - 项目类别:
Development of Vaccines against Clostridium difficile Infection
艰难梭菌感染疫苗的研制
- 批准号:
7903007 - 财政年份:2010
- 资助金额:
$ 60.86万 - 项目类别:
相似海外基金
Investigating how TRAF1 Controls Inflammasome Activation in Animal Disease Models of Inflammatory Arthritis and Peritonitis
研究 TRAF1 如何控制炎症性关节炎和腹膜炎动物疾病模型中的炎症小体激活
- 批准号:
449429 - 财政年份:2020
- 资助金额:
$ 60.86万 - 项目类别:
Studentship Programs
Establishment of animal disease models for intractable pediatric diseases due to defects of RNA metabolism and development of new therapeutics
RNA代谢缺陷引起的儿科疑难疾病动物模型的建立及新疗法的开发
- 批准号:
20H03644 - 财政年份:2020
- 资助金额:
$ 60.86万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Functional analysis of type 2 diabetes susceptibility genes using animal disease models
利用动物疾病模型对2型糖尿病易感基因进行功能分析
- 批准号:
18K08466 - 财政年份:2018
- 资助金额:
$ 60.86万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Cell therapy of adipocytes derived from human iPS cells using cellcontainers and animal disease models
使用细胞容器和动物疾病模型对源自人类 iPS 细胞的脂肪细胞进行细胞治疗
- 批准号:
24659444 - 财政年份:2012
- 资助金额:
$ 60.86万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Analysis of genes involved in the pathogenesis of the arthritis using animal disease models..
使用动物疾病模型分析涉及关节炎发病机制的基因。
- 批准号:
17500284 - 财政年份:2005
- 资助金额:
$ 60.86万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
ESTABLISHMENT OF THE DEVELOPING AND SUPPLING SYSTEMS FOR NEW ANIMAL,DISEASE MODELS FROM SUBSPECIES OF THE MOUSE
小鼠亚种新动物、疾病模型的开发和供应体系的建立
- 批准号:
07556128 - 财政年份:1995
- 资助金额:
$ 60.86万 - 项目类别:
Grant-in-Aid for Scientific Research (A)














{{item.name}}会员




